Luminex Corporation Third Quarter Earnings Release Scheduled for November 4, 2009

Management will hold a conference call to discuss the operating
highlights and financial results for the third quarter ended September
30, 2009, on November 4, 2009, at 5:00 p.m. Eastern time.

The conference call will be webcast live and will be accompanied by a
slide presentation, both of which may be accessed at Luminex
Corporation's website at http://www.luminexcorp.com.
Simply log on to the web at the address above, go to the Company section
and access the Investor Relations link. Please go to the website at
least 15 minutes prior to the call to register, download and install any
necessary audio/video software. If you are unable to participate during
the live webcast, the call and slides will be archived for six months on
the website using the 'replay' link.

The use of pop-up blocking software may impair your ability to view
webcasts. If you use this software, press and hold the CTRL key when you
click on the Register button. Please contact your IT group if you are
unable to override this feature. Unauthorized recording or downloading
of this event is not permitted.

About Luminex Corporation

Luminex Corporation develops, manufactures and markets proprietary
biological testing technologies with applications throughout the
diagnostic and life sciences industries. The Company's xMAP(R) multiplex
solutions include an open-architecture, multi-analyte technology
platform that delivers fast, accurate and cost-effective bioassay
results to markets as diverse as pharmaceutical drug discovery, clinical
diagnostics and biomedical research, including the genomics and
proteomics research markets. The Company's xMAP technology is sold
worldwide and is already in use in leading clinical laboratories as well
as major pharmaceutical, diagnostic and biotechnology companies. Further
information on Luminex Corporation or xMAP technology can be obtained at www.luminexcorp.com.

Statements made in this release that express Luminex's or
management's intentions, plans, beliefs, expectations or predictions of
future events are forward-looking statements. The words "believe,"
"expect," "intend," "estimate," "anticipate," "will," "could," "should"
and similar expressions are intended to further identify such
forward-looking statements for purposes of the Private Securities
Litigation Reform Act of 1995. It is important to note that the
Company's actual results or performance could differ materially from
those anticipated or projected in such forward-looking statements.
Factors that could cause Luminex's actual results or performance to
differ materially include risks and uncertainties relating to, among
others, market demand and acceptance of Luminex's products, the
Company's dependence on strategic partners for development,
commercialization and distribution of products, concentration of the
Company's revenue in a limited number of strategic partners,
fluctuations in quarterly results due to a lengthy and unpredictable
sales cycle and bulk purchases of consumables, Luminex's ability to
scale manufacturing operations and manage operating expenses, gross
margins and inventory levels, potential shortages of components,
competition, the timing of regulatory approvals, the implementation,
including any modification, of the Company's strategic operating plans,
risks and uncertainties associated with implementing our acquisition
strategy and the ability to integrate acquired companies or selected
assets into our consolidated business operations, as well as the risks
discussed under the heading "Risk Factors" in Luminex's Reports on Forms
10-K and 10-Q, as filed with the Securities and Exchange Commission. The
forward-looking statements contained herein represent the judgment of
Luminex as of the date of this press release, and Luminex expressly
disclaims any intent, obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements to reflect any
change in Luminex's expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements are
based.

SOURCE: Luminex Corporation

Luminex 
Harriss T. Currie, Vice President, Finance and Chief Financial Officer, 512-219-8020 
hcurrie@luminexcorp.com 
or 
Investor Relations 
Mimi Torrrington, Director of Investor Relations, 512-219-8020 
mtorrington@luminexcorp.com

For full details on Luminex Corporation (LMNX) LMNX. Luminex Corporation (LMNX) has Short Term PowerRatings at TradingMarkets. Details on Luminex Corporation (LMNX) Short Term PowerRatings is available at This Link.